

RAS intrinsic GTPase activity hydrolyzes

GTP to GDP

Gavathiotis, E., Rothfels, K.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](https://creativecommons.org/licenses/by/4.0/). For more information see our [license](https://reactome.org/licenses/).

02/05/2024

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 88


This document contains 1 reaction ([see Table of Contents](#))

RAS intrinsic GTPase activity hydrolyzes GTP to GDP ↗

Stable identifier: R-HSA-9649736

Type: transition

Compartments: plasma membrane



RAS proteins have weak intrinsic GTPase activity in the absence of other effectors (Gibbs et al, 1984; reviewed in Pylayeva-Gupta et al, 2011). Nucleotide attack is mediated by residue Q61 and facilitated by van der Waals bonds contributed by glycine residues at position 12 and 13; these three residues account for the majority of oncogenic and pathogenic mutations found in RAS proteins (reviewed in Prior et al, 2012). GAP proteins stimulate the intrinsic GTPase activity of RAS proteins by inserting an arginine residue into the active site, which contributes to proper positioning of the critical Q61 RAS residue (reviewed in King et al, 2013).

Literature references

- Grabocka, E., Pylayeva-Gupta, Y., Bar-Sagi, D. (2011). RAS oncogenes: weaving a tumorigenic web. *Nat. Rev. Cancer*, 11, 761-74. ↗
- Lapinski, PE., Lubeck, BA., King, PD. (2013). Nonredundant functions for Ras GTPase-activating proteins in tissue homeostasis. *Sci Signal*, 6, re1. ↗
- Lewis, PD., Mattos, C., Prior, IA. (2012). A comprehensive survey of Ras mutations in cancer. *Cancer Res.*, 72, 2457-67. ↗
- Sigal, IS., Scolnick, EM., Gibbs, JB., Poe, M. (1984). Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. *Proc. Natl. Acad. Sci. U.S.A.*, 81, 5704-8. ↗

Editions

2019-10-25	Authored	Rothfels, K.
2020-05-04	Reviewed	Gavathiotis, E.
2020-05-26	Edited	Rothfels, K.